images (2)

npp side effects

Experience post-registration of the drug: – In addition to the above adverse reactions that arise when taking the drug npp side effects , below lists the adverse reactions, which may refer to the treatment . The incidence of these adverse reactions may be classified testosterone pills uk as very rare (<1/10000 patient-years):

  • Benign and malignant tumors (including cysts and polyps): Endometrial cancer
  • Mental disorders: insomnia, anxiety, libido change
  • Disorders of the nervous system: dizziness, cerebrovascular accident
  • Violations of the organ of vision: visual impairment
  • Violations of the vessels: aggravation of hypertension
  • Violations of the heart: myocardial infarction
  • Disorders of the gastrointestinal tract: dyspepsia, vomiting
  • Disorders of the liver and biliary tract: cholecystitis, cholelithiasis, cholelithiasis exacerbation
  • Disorders of the skin and subcutaneous tissue: seborrhea, rash, angioedema
  • Violations of the genital organs and the breast: vulvovaginal pruritus
  • Other: weight loss, increased blood pressure.Breast Cancer – According to a large number of epidemiological studies and one randomized placebo-controlled study conducted by the npp side effects “Women’s Right to Health┬╗ , the overall risk of breast cancer increases with increasing duration use rate. Relative Risk assessment, obtained in the re-analysis of original data 51 epidemiological studies (in which more than 80% of women took with estrogen alone course) and the result of analysis of epidemiological studies “Million women┬╗ , are almost identical: 1.35 (confidence interval 95 %, 1.21 – 1.49) and 1.30 (95% confidence interval, 1.21 -. 1.40), respectively, results of individual epidemiological studies indicate generally higher risk of developing breast cancer in women undergoing course combined HRT (estrogen plus progestogen), compared with those who took only estrogen. These studies MWS indicate that, compared with women who never passed a course testosteron propionat, the use of different types of combined (estrogen plus progestogen) npp side effectsis associated with higher risk of developing breast cancer (RR = 2.00, 95% confidence interval: 1.88 – 2.12) compared with those who took only estrogen . According study for all women undergoing a course of combined (estrogen plus progestogen) . compared with placebo Absolute risk indicators are calculated according studies are presented below: Using well-known in the average share of women’s diseases breast cancer in developed countries, in the study found that:
  • Breast cancer is diagnosed in about 32 of the 1,000 women npp side effects who do not use, aged between 50 and 64 years.
  • In 1000 women undergoing hormone replacement therapy or have recently passed the course tne steroid, the number of additional cases of breast cancer during the corresponding period will be: When estrogen-only replacement therapy
  • between 0 and 3 (best estimate = 1.5) for 5-year course
  • between 3 and 7 (best estimate = 5) for 10 years to date for combined estrogen plus progestogen HRT
  • between 5 and 7 (best estimate = 6) for 5-year course
  • between 18 and 20 (best estimate = 19) for 10 years of the course. In a study conducted by the WHI, found that after treatment duration of 5.6 years in women aged between 50 and 79 years, the development of additional 8 cases of invasive breast cancer by 10 000 women could be due to the combined estrogen plus progestogen Based on the calculation carried out in the study found that:
  • For 1000 women who took a placebo, about 16 cases of invasive breast cancer can be diagnosed in 5 years.
  • For 1000 women who took combined estrogen plus progestogen npp side effects, the number of additional cases would be between 0 – 9 (best estimate = 4) for 5 years of use. The number of additional cases of breast cancer in women, who take drugs HRT is similar for women who started HRT, regardless of age to the beginning of treatment (age between 45 and 65 years).endometrial cancer – The risk of endometrial hyperplasia and endometrial cancer in women with an intact uterus increases with the duration of receiving only estrogen . According to data from epidemiological studies on the most accurate risk assessment is expected that about 5 in 1,000 women, does not pass the course, endometrial cancer can be diagnosed at the age between 50 and 65 years. Depending on the duration of treatment and estrogen dose trenabol results, the increase in endometrial cancer risk among patients taking only estrogen, according to available data varies from 2 to 12 times, compared with patients not taking estrogen. Adding a progestogen to estrogen-only monotherapy significantly reduces this risk. Other adverse reactions that have been reported in connection with the treatment of a combination of estrogen / progestogen include:
  • Disorders of the skin and subcutaneous tissue disorders: chloasma, exudative erythema multiforme, erythema nodosum, vascular purpura.